Suppr超能文献

需要普通肝素抗凝的儿科患者使用抗凝血酶浓缩剂:一项回顾性队列研究。

Antithrombin concentrate in pediatric patients requiring unfractionated heparin anticoagulation: a retrospective cohort study.

作者信息

Ryerson Lindsay M, Bauman Mary E, Kuhle Stefan, Bruce Aisha A, Massicotte M Patricia

机构信息

1Pediatric Critical Care, Stollery Children Hospital, University of Alberta, Edmonton, AB, Canada. 2Pediatric Cardiology-Thrombosis, Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada. 3Departments of Pediatrics and Obstetrics and Gynaecology, Dalhousie University, Halifax, NS, Canada. 4Department of Hematology, Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada. 5Pediatric Cardiology-Thrombosis, Stollery Children's Hospital, Edmonton, AB, Canada.

出版信息

Pediatr Crit Care Med. 2014 Oct;15(8):e340-6. doi: 10.1097/PCC.0000000000000174.

Abstract

OBJECTIVE

To describe antithrombin levels, altered unfractionated heparin effect (anti-factor Xa activity and activated partial thromboplastin time), and adverse effects post administration of a single high dose of antithrombin concentrate.

DESIGN

Retrospective review.

PATIENTS

Infants and children with antithrombin levels less than 50% and a subtherapeutic unfractionated heparin effect.

SETTING

Quaternary care children's hospital with a dedicated anticoagulation program.

INTERVENTIONS

None.

MEASUREMENTS AND MAIN RESULTS

A single high dose of antithrombin concentrate was administered. Antithrombin level, anti-factor Xa, and activated partial thromboplastin times were measured post antithrombin concentrate infusion and daily until stable. One hundred twenty-one patients received 246 doses of antithrombin. Patients were described using two cohorts based on the ability to obtain exact heparin doses. Cohort 1 included all patients between January 2004 and May 2008 when complete heparin dosing was unavailable. Cohort 2 included patients from May 2008 to May 2011 when heparin dose was available. Median age and weight were 3.7 months and 4.1 kg. Mean antithrombin concentrate dose was 222 IU/kg. Mean antithrombin level increased from 0.39 to 1.20 U/mL following antithrombin concentrate administration. In cohort 2, unfractionated heparin doses to achieve a target anti-factor Xa activity pre-post antithrombin concentrate were 28 and 19 U/kg/hr, respectively, for children 12 months old or younger and 25 and 19 U/kg/hr, respectively, for children older than 12 months. There were no hemorrhagic, thrombotic, or allergic events within 1 week of antithrombin concentrate administration.

CONCLUSIONS

This is the largest study of antithrombin concentrate evaluation in children. Administration of antithrombin concentrate increases anti-factor Xa activity with lower administered unfractionated heparin doses.

摘要

目的

描述单次高剂量抗凝血酶浓缩物给药后的抗凝血酶水平、普通肝素效应改变(抗Xa因子活性和活化部分凝血活酶时间)及不良反应。

设计

回顾性研究。

患者

抗凝血酶水平低于50%且普通肝素效应未达治疗水平的婴幼儿及儿童。

地点

设有专门抗凝项目的四级儿童专科医院。

干预措施

无。

测量指标及主要结果

给予单次高剂量抗凝血酶浓缩物。在输注抗凝血酶浓缩物后及每日测量直至稳定,测定抗凝血酶水平、抗Xa因子及活化部分凝血活酶时间。121例患者接受了246剂抗凝血酶。根据获取准确肝素剂量的能力,将患者分为两个队列。队列1包括2004年1月至2008年5月期间所有无法获得完整肝素剂量的患者。队列2包括2008年5月至2011年5月期间可获得肝素剂量的患者。中位年龄和体重分别为3.7个月和4.1千克。抗凝血酶浓缩物平均剂量为222 IU/kg。给予抗凝血酶浓缩物后,平均抗凝血酶水平从0.39 U/mL升至1.20 U/mL。在队列2中,12个月及以下儿童在抗凝血酶浓缩物给药前后达到目标抗Xa因子活性所需的普通肝素剂量分别为28 U/kg/hr和19 U/kg/hr,12个月以上儿童分别为25 U/kg/hr和19 U/kg/hr。在抗凝血酶浓缩物给药后1周内未发生出血、血栓形成或过敏事件。

结论

这是关于儿童抗凝血酶浓缩物评估的最大规模研究。给予抗凝血酶浓缩物可提高抗Xa因子活性,同时降低普通肝素给药剂量。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验